SCHEMBL4104239

SCHEMBL4104239

Cc1cc(C(=O)C(C)Br)ccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.46
SLC6A4 P31645 3/20 0.46
SLC6A3 Q01959 3/20 0.46
CHRNA1 P02708 2/20 0.46
CHRNG P07510 2/20 0.46
CHRNB1 P11230 2/20 0.46
CHRNB2 P17787 2/20 0.46
CHRNB4 P30926 2/20 0.46
CHRNA3 P32297 2/20 0.46
CHRNA4 P43681 2/20 0.46
CHRND Q07001 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
ALDH1A1 P00352 1/20 0.46
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
TAS1R2 Q8TE23 1/20 0.46
MEN1 O00255 1/20 0.42
PKM P14618 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26241547 0.88 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL634550 0.87 SLC6A2 (0.60) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL2237695 0.87 GAA (0.53) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL633270 0.87 TSHR (0.53) SLC6A2SLC6A4SLC6A3CYP1A2CYP2C9
SCHEMBL10026169 0.85 ALDH1A1 (0.49) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL10825703 0.83 TAS1R3 (0.47) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL18527134 0.82 ALDH1A1 (0.44) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL10728309 0.81 KDM4E (0.52) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL633275 0.81 CHRNA1 (0.62) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL10825712 0.81 TAS1R3 (0.46) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221645-A1 Dihydroimidazothiazole Derivatives PROSIDION LIMITED (GB) 2009-09-03 US disclosed
US-20090221645-A1 Dihydroimidazothiazole Derivatives PROSIDION LIMITED (GB) 2009-09-03 US disclosed
US-20090221645-A1 Dihydroimidazothiazole Derivatives PROSIDION LIMITED (GB) 2009-09-03 US disclosed
EP-1851232-A2 DIHYDROIMIDAZOTHIAZOLE DERIVATIVES Prosidion Limited (GB) 2007-11-07 EP disclosed
WO-2006085118-A2 DIHYDROIMIDAZOTHIAZOLE DERIVATIVES PROSIDION LIMITED (GB) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221645-A1 Dihydroimidazothiazole Derivatives TPH1, HTR3B, HTR1A SLC6A2 10/4885SLC6A4 8/4885SLC6A3 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.